![Mark Chao](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Chao
Fondatore presso
FORTY SEVEN, INC.
Profilo
Mark Chao is the founder of Hepatx Corp.
(2015), Forty Seven LLC (2014), and TenSixteen Bio, Inc. (2021).
Dr. Chao is also the founder of Gilead Sciences, Inc. Dr. Chao is currently an Advisor at Bioverge Funds Management LLC, a Venture Partner at Foresite Labs LLC, a Scientific Advisory Board Member at IconOVir Bio, Inc., and a Scientific Advisory Board Member at TigaTx, Inc. Education includes a graduate degree from Stanford University (2011), an undergraduate degree from Case Western Reserve University (2004), and both a graduate degree and a doctorate from Stanford University School of Medicine (2011).
Posizioni attive di Mark Chao
| Società | Posizione | Inizio |
|---|---|---|
| FORTY SEVEN, INC. | Fondatore | 01/01/2014 |
Foresite Labs LLC
 Foresite Labs LLC Miscellaneous Commercial ServicesCommercial Services Provides incubation platform services | Investitore di Private Equity | 01/01/2021 |
IconOVir Bio, Inc.
 IconOVir Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops oncolytic virus therapy to improve the treatment of patients with cancer | Consulente / Consigliere | 01/12/2021 |
TigaTx, Inc.
 TigaTx, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops engineered immunoglobulin to create isotype cancer antibody | Consulente / Consigliere | 01/05/2020 |
Bioverge Funds Management LLC
 Bioverge Funds Management LLC Investment ManagersFinance Bioverge Funds Management invests in companies located in the United States. The firm targets companies operating in the fields of healthcare and technology. It provides financing for seed and early stage capital requirements. | Consulente / Consigliere | - |
Precedenti posizioni note di Mark Chao
| Società | Posizione | Fine |
|---|---|---|
TenSixteen Bio, Inc.
 TenSixteen Bio, Inc. BiotechnologyHealth Technology Develops novel therapeutics to treat age-related diseases | Amministratore Delegato | 01/01/2023 |
| GILEAD SCIENCES, INC. | Fondatore | - |
Hepatx Corp.
 Hepatx Corp. Packaged SoftwareTechnology Services Develops stem cell technology for liver diseases | Fondatore | - |
Formazione di Mark Chao
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
88
Relazioni di 1° grado
11
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 11 |
|---|---|
Gilead Sciences, Inc.
 Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Case Western Reserve University
 Case Western Reserve University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Forty Seven, Inc.
 Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for cancer treatment | Health Technology |
Stanford University School of Medicine
 Stanford University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bioverge Funds Management LLC
Bioverge Funds Management LLC Investment ManagersFinance Bioverge Funds Management invests in companies located in the United States. The firm targets companies operating in the fields of healthcare and technology. It provides financing for seed and early stage capital requirements. | Finance |
Hepatx Corp.
Hepatx Corp. Packaged SoftwareTechnology Services Develops stem cell technology for liver diseases | Technology Services |
Foresite Labs LLC
Foresite Labs LLC Miscellaneous Commercial ServicesCommercial Services Provides incubation platform services | Commercial Services |
IconOVir Bio, Inc.
IconOVir Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops oncolytic virus therapy to improve the treatment of patients with cancer | Health Technology |
TenSixteen Bio, Inc.
TenSixteen Bio, Inc. BiotechnologyHealth Technology Develops novel therapeutics to treat age-related diseases | Health Technology |
TigaTx, Inc.
TigaTx, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops engineered immunoglobulin to create isotype cancer antibody | Health Technology |
